1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Brooks Laboratories Limited

Brooks Laboratories Limited

58.02
INR
-3.55
(-5.77%)
4.50EPS
15.32P/E
2.03BMarket Cap
Brooks Laboratories Limited
BSE:BROOKS
(Bombay Stock Exchange)

Recent

price

58.02

P/E

ratio

15.32

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
44.16
28.61
40.87
43.5
43.47
40.82
29.35
28.42
39.73
38.88
30.88
36.12
25.29
30.84
30.68
28.98
28.34
Revenue per Share
5.79
4.51
3.64
3.69
4.83
5.42
0.85
-7.05
-10.69
-13.71
-7.77
-7.74
-8.46
-7.65
-3.72
8.35
4.5
Basic EPS, GAAP
2.55
-12.14
1.72
4.42
-9.12
-14.18
-4.11
-6.08
-4.27
-6.73
-0.46
-24.32
-6.06
-4
0.64
1.96
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
16.23
46.56
53.77
57.29
56.84
64.54
65.44
58.4
53.64
39.45
31.73
35.07
29.65
24.99
33.3
41.64
- -
Book Value per Share
16.23
46.56
53.77
57.29
56.84
64.54
65.44
58.4
53.45
39.34
31.45
34.82
29.57
24.96
33.3
41.64
- -
Tangible Book Value per Share
12
20
20
20
20
20
20
20
14
18
25
25
25
26
27
29
29
Basic Weighted Avg Shares
525
561
801
853
852
800
575
557
550
691
770
901
625
790
822
854
832
Sales/Revenue/Turnover
16.57
17.52
12.1
9.02
7.22
12.79
5.86
-27.59
-22
-13.37
-8.57
-24.09
-53.7
1.83
7.94
6.41
5.03
Operating Margin (%)
6
7
8
8
11
12
17
64
65
66
71
74
70
18
16
16
16
Depreciation Expense
69
88
71
72
95
106
17
-138
-148
-244
-194
-193
-209
-196
-100
246
132
Net Income, GAAP
4.19
3.64
25.45
4.38
8.53
1.71
32.86
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
13.11
15.76
8.92
8.49
11.11
13.29
2.9
-24.79
-26.9
-35.26
-25.15
-21.44
-33.44
-24.8
-12.13
28.79
15.88
Profit Margin (%)
-26
278
416
367
326
16
-24
-98
-157
-79
-163
123
-54
80
110
156
- -
Working Capital
9
- -
- -
- -
- -
3
107
166
139
119
144
101
6
4
14
21
- -
LT Debt
194
913
1,054
1,123
1,114
1,265
1,283
1,145
1,052
984
791
1,343
740
656
981
1,227
- -
Total Equity
25.72
14.68
7.19
6.61
8.41
8.69
1.5
- -
- -
- -
- -
- -
- -
- -
- -
5
- -
Return on Invested Capital (%)
25.72
14.68
7.19
6.69
8.61
9.31
1.65
- -
- -
- -
- -
- -
- -
- -
- -
21.36
- -
Return on Capital (%)
41.66
15.97
7.26
6.65
8.46
8.94
1.31
-11.38
-13.48
-23.95
-21.82
-23.18
-25.88
-28.08
-12.18
22.27
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
64
- -
LT Borrowings
- -
12
- -
LT Finance Leases
- -
9
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
29
29
29
Market Capitalization
2,364
1,104
2,031

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
374
- -
Cash, Cash Equivalents & STI
- -
79
- -
Accounts Receivable, Net
- -
161
- -
Inventories
- -
110
- -
Total Current Liabilities
- -
218
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
64
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
4.46%
17.61%
25.03%
Free Cash Flow
510.64%
1,033.57%
239.75%
Net Income, GAAP
-135.58%
-78.83%
-346.65%
Sales/Revenue/Turnover
2.52%
4.13%
3.88%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
179
208
205
233
822
2026
255
235
166
202
854
2027
230
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
-0.94
-1.51
-0.82
-0.54
-3.72
2026
3.25
2.71
1.87
0.52
8.35
2027
-0.61
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Brooks Laboratories Limited (BROOKS.NS), a research-driven pharmaceutical contract development and manufacturing organization (CDMO), manufactures sterile injectables and oral dosage forms for pharmaceutical companies in India and internationally. The company offers dry powder injections, liquid injections, general injectables, Beta Lactam tablets, Beta Lactam injections and suspensions, oral suspensions, eye/ear drops, and cephalosporin products; it specializes in critical care formulations including carbapenems through its joint venture subsidiary Brooks SteriScience Limited. Founded in 2002 and headquartered in Mumbai, India, Brooks Laboratories operates WHO-GMP certified manufacturing facilities in Baddi, Himachal Pradesh, and Vadodara, Gujarat, with accreditations from regulatory authorities in Nigeria, Cambodia, Ivory Coast, Yemen, Vietnam, Syria, and the Democratic Republic of Congo. The company exports to markets including Venezuela, Mauritius, Colombia, Uzbekistan, Kosovo, Kenya, Latin America, and other regions in the Rest of World (ROW) and semi-regulated countries. In recent developments, Brooks Laboratories continues expansion through strategic alliances for product registrations in global markets and maintains its carbapenem business via the SteriScience joint venture, which received USFDA approval for the Vadodara facility and focuses on penetrating regulated markets such as the US, Europe, Canada, Australia, and India.